Palvella Therapeutics (PI6) Price & Analysis

0 Followers

PI6 Stock Chart & Stats

€126.00

€2.00(1.63%)

At close: Jul 24 4:00 PM EDT

€126.00

€2.00(1.63%)

Day’s Range― - ―

52-Week Range€64.00 - €137.00

Previous CloseN/A

Volume0.00

Average Volume (3M)12.00

Market Cap

€1.88B

Enterprise Value€1.97B

Total Cash (Recent Filing)€250.58M

Total Debt (Recent Filing)€535.00K

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Nov 05, 2026

EPS Estimate

-1.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.83

Shares Outstanding14,408,407

10 Day Avg. Volume0

30 Day Avg. Volume12

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)42.09

Price to Sales (P/S)0.00

P/FCF Ratio-47.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€206.92

Price Target Upside64.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-5.92

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory ProgressPriority Review and an assigned action date create a defined regulatory path for QTORIN in microcystic lymphatic malformations. This materially advances the company toward its first potential approval and could support a transition from clinical development to commercial operations.

Clinical EfficacyBroad success across the pivotal trial endpoints, including improvement in 95% of patients, provides substantial support for QTORIN’s efficacy profile. Strong clinical differentiation can improve the probability of approval and underpin adoption in a serious rare disease with limited treatment options.

Financial ResourcesA substantial cash balance and successful financing provide resources to complete regulatory work, prepare commercial infrastructure and advance the pipeline. This reduces immediate financing pressure and gives management greater flexibility to execute over the next several quarters.

Bears Say

No Commercial RevenueThe absence of current product revenue means Palvella has not yet demonstrated a commercial earnings base. Financial performance therefore remains dependent on future regulatory approval and launch execution, leaving limited operating diversification while the company remains pre-commercial.

Persistent Cash BurnContinued negative free cash flow requires Palvella to fund research, regulatory and launch activities from existing capital or future financing. Even with improving burn direction, ongoing losses can reduce financial flexibility and increase dilution risk before commercial cash generation begins.

Long Development TimelinesExpansion beyond the initial microcystic lymphatic malformation opportunity depends on additional pivotal studies and multi-year regulatory timelines. Delayed contribution from later indications increases reliance on the first launch and extends the period before the broader platform can diversify revenue.

Palvella Therapeutics News

Palvella Therapeutics price target lowered to $232 from $240 at Mizuho

Mizuho lowered the firm’s price target on Palvella Therapeutics (PVLA) to $232 from $240 and keeps an Outperform...

3d ago

PVLA

Palvella Therapeutics announces FDA acceptance, priority review for Qtorin NDA

Palvella Therapeutics (PVLA) announced that the FDA has accepted for filing and granted Priority Review to the company’s...

4d ago

PVLA

Clear Street sees positive read for Palvella from FDA rare disease framework

Noting that the FDA launched its Rare Disease Framework Initiative on October 14, Clear Street sees “meaningful positive...

11d ago

PVLA

Raymond James says new data supportive of broad label for Qtorin

Raymond James analyst Ryan Deschner keeps a Strong Buy rating on Palvella Therapeutics (PVLA) announced yesterday morning the...

16d ago

PVLA

Palvella Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating. Palvella is a rare disease company...

16d ago

PVLA

Palvella Therapeutics price target lowered to $246 from $270 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Palvella Therapeutics (PVLA) to $246 from $270 and keeps a...

20d ago

PVLA

Palvella Therapeutics management to meet with Truist

Meeting to be held in Boston on October 6 hosted by Truist. Published first on TheFly – the...

26d ago

PVLA

Palvella Gains FDA Priority Review for QTORIN Gel

The latest update is out from Palvella Therapeutics ( ($PVLA) ). On October 28, 2026, Palvella Therapeutics announced...

4d ago

PVLA

Palvella receives third year of grant funding from FDA for QTORIN

Palvella Therapeutics (PVLA) announced that the Company has received a third year of grant funding from the FDA...

1M ago

PVLA

Palvella Therapeutics transferred with Buy rating at Chardan

Chardan kept a Buy rating on Palvella Therapeutics (PVLA) with a $240 price target following a transfer of...

1M ago

PVLA

Palvella Therapeutics completes rolling submission of Qtorin NDA to FDA

Palvella Therapeutics (PVLA) announced that the company has completed the rolling submission of its new drug application, or...

2M ago

PVLA

Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating

In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Palvella Therapeutics, with...

3M ago

PVLA

High-Risk Warning for Investors in Palvella Therapeutics Securities

Palvella Therapeutics, Inc. (PVLA) has disclosed a new risk, in the Regulation category. An external review indicates that...

3M ago

PVLA

Palvella Therapeutics Charts Clear Path From Data To Launch

Palvella Therapeutics, Inc. (($PVLA)) has held its Q2 earnings call. Read on for the main highlights of the...

3M ago

PVLA

PI6 FAQ

What was Palvella Therapeutics’s price range in the past 12 months?

Palvella Therapeutics lowest stock price was €64.00 and its highest was €137.00 in the past 12 months.

What is Palvella Therapeutics’s market cap?

Palvella Therapeutics’s market cap is €1.88B.

When is Palvella Therapeutics’s upcoming earnings report date?

Palvella Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.

How were Palvella Therapeutics’s earnings last quarter?

Palvella Therapeutics released its earnings results on Aug 04, 2026. The company reported -€1.356 earnings per share for the quarter, missing the consensus estimate of -€1.047 by -€0.31.

Is Palvella Therapeutics overvalued?

According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palvella Therapeutics pay dividends?

Palvella Therapeutics does not currently pay dividends.

What is Palvella Therapeutics’s EPS estimate?

Palvella Therapeutics’s EPS estimate is -1.59.

How many shares outstanding does Palvella Therapeutics have?

Palvella Therapeutics has 14,408,407 shares outstanding.

What happened to Palvella Therapeutics’s price movement after its last earnings report?

Palvella Therapeutics reported an EPS of -€1.356 in its last earnings report, missing expectations of -€1.047. Following the earnings report the stock price went up 1.681%.

Which hedge fund is a major shareholder of Palvella Therapeutics?

Currently, no hedge funds are holding shares in DE:PI6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Palvella Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.84%

Trailing 12-Months

Asset Growth

243.76%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Palvella Therapeutics

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Palvella Therapeutics (PI6) Earnings & Revenues

Historic Earnings Reports

PI6 Company Deck

PI6 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights substantial clinical and regulatory progress—compelling Phase III SELVA results (95% improvement on primary endpoint), rolling review and first NDA module submission—supported by strong financial resources (~$251M cash) and accelerated commercial hiring (≈40 reps). Near-term risks include the need to complete the NDA, initial lack of Breakthrough for cVM (to be addressed with additional 24‑week data and qualitative evidence), increased 2026 cash spend to accelerate launch readiness, and multi-year timelines to expand indications beyond microcystic LMs. Overall, the positive clinical data, regulatory momentum, funding and clear commercial plan meaningfully outweigh the challenges and remaining execution risks.View all DE:PI6 earnings summaries

PI6 Stock 12 Month Forecast

Average Price Target

€206.92

▲(64.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"€52","239":"€239","98.75":"€98.8","145.5":"€145.5","192.25":"€192.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":238.39094199,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€238.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":206.91798054749998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€206.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":184.81994379,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€184.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,98.75,145.5,192.25,239],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121,130.03007246076922,139.06014492153847,148.09021738230769,157.12028984307693,166.15036230384615,175.18043476461537,184.21050722538462,193.24057968615384,202.27065214692306,211.3007246076923,220.33079706846152,229.36086952923074,{"y":238.39094199,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121,127.60907542673077,134.21815085346154,140.8272262801923,147.43630170692308,154.04537713365383,160.6544525603846,167.26352798711537,173.87260341384615,180.4816788405769,187.09075426730766,193.69982969403844,200.30890512076923,{"y":206.91798054749998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121,125.90922644538462,130.81845289076924,135.72767933615384,140.63690578153847,145.54613222692308,150.45535867230768,155.3645851176923,160.27381156307692,165.18303800846155,170.09226445384616,175.00149089923076,179.91071734461536,{"y":184.81994379,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >